Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET.
Article content
Article content
Ventus Therapeutics is a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
AuditBoard Recognized as a Leader for Governance, Risk, and Compliance Software by Independent Analyst Firm
Connected risk platform achieved joint highest scores for AI, audit management, vision, innovation, and product strategy. LOS ANGELES, Aug. 19, 2025 /CNW/ -- AuditBoard, the AI-powered global platform for connected risk transforming audit, risk, and compliance, today announced it was named a Leader in the annual Verdantix Green Quadrant: GRC Software 2025 Report, earning joint highest scores for its AI, product vision, and strategy. This is another significant milestone as AuditBoard continues on its mission to be the category-defining global platform for connected risk, elevating customers through innovation. AuditBoard has consistently been recognized for its industry-leading platform and rapid growth. The company was recently named a Leader in the IDC MarketScape Worldwide Governance, Risk, and Compliance Software 2025 Vendor Assessment (doc # US53615325, June 2025) and a Representative Vendor in 2025 Gartner® Market Guide for Third-Party Risk Management Technology Solutions. AuditBoard also recently announced it serves more than 50% of the Fortune 500. "Being named a Leader in the Verdantix Green Quadrant: GRC Software 2025 Report further exemplifies how well our customer-centric approach is working," said Happy Wang, Chief Product and Technology Officer at AuditBoard. "By actively incorporating customer feedback into our product roadmap, we are able to provide the tools they need to strengthen risk decision-making, enhance organizational resiliency, and unlock new avenues for revenue growth." "AuditBoard's connected risk platform has revolutionized our entire risk management strategy," said Fred Friedel, VP Internal Audit and Enterprise Risk at Interactive Communications International, Inc. "We've been able to break down siloes, improve collaboration, and dramatically reduce the time we spend on manual tasks. AuditBoard has allowed our team to be more efficient and ultimately provide more value to our business." "AuditBoard is a suitable choice for organizations looking to centralize risk management around audit and compliance workflows," said Katelyn Johnson, Senior Manager, Verdantix. "The platform supports greater efficiency in audit execution by reducing manual tasks and supporting structured workflows. In compliance, its automation features help maintain oversight and support timely documentation and reporting. Among the platforms evaluated in this report, AuditBoard shows particular strength in tailoring AI capabilities to this domain." To learn more about AuditBoard's connected risk platform, read the full report here. About AuditBoard AuditBoard's mission is to be the category-defining global platform for connected risk, elevating our customers through innovation. More than 50% of the Fortune 500 trust AuditBoard to transform their audit, risk, and compliance management. AuditBoard is top-rated by customers on G2, Capterra, and Gartner Peer Insights, and was recently ranked for the sixth year in a row as one of the fastest-growing technology companies in North America by Deloitte.
Globe and Mail
3 hours ago
- Globe and Mail
Palantir Stock's Valuation: Overstretched or Rightfully Earned?
Palantir Technologies PLTR has emerged as one of the most talked-about names in the S&P 500, and not just for what it does, but for what investors are willing to pay for it. With a market capitalization of $420 billion, it now surpasses giants like Coca-Cola and Bank of America. Yet, when viewed through a valuation lens, Palantir stands alone in its league. Its trailing 12-month price-to-earnings ratio exceeds 580X, and its forward 12-month multiple hovers above 225X. Even more striking is its enterprise value relative to forward 12-month revenues of more than 82X, a level rarely seen, even during the most exuberant periods in market history. By that metric, Palantir looks far more expensive than nearly every other established U.S. stock over the past two decades. Such elevated valuations raise the bar for future performance. For a company trading at these levels, expectations around revenue acceleration, margin expansion and long-term scalability must not only be met, but also exceeded. Even minor disappointments can trigger sharp corrections as multiples revert toward historical norms. Companies in the past that reached these kinds of revenue multiples — often 30x or higher — eventually faced tough questions about sustainability. Optimism alone is rarely sufficient when fundamentals lag. That said, Palantir's expanding government and commercial contracts, its robust and evolving AI platforms, and consistent execution lend credibility to its premium valuation. While risks remain, we view Palantir as one of the most compelling long-term AI plays available today. PLTR's Price Performance, Estimates The stock has surged a whopping 130% year to date, significantly outperforming the industry 's 23% rally. The Zacks Consensus Estimate for PLTR's earnings has increased 21.4% over the past 30 days. PLTR stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Stable Defense Alternatives to Palantir As PLTR's valuation moves higher, Lockheed Martin LMT and RTX Corporation RTX offer more grounded defense exposure. Lockheed Martin, with its massive defense contracts, provides steady cash flow and less volatility than PLTR. Its trailing 12-month price-to-earnings ratio is below 25X, and its forward 12-month multiple is just above 16X. Lockheed Martin continues to benefit from global rearmament while trading at modest earnings multiples. Similarly, RTX shines through missile systems. RTX's defense backlog, like LMT's, underscores its stability. Its trailing 12-month price-to-earnings ratio is below 34X and its forward 12-month multiple is just above 24X. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RTX Corporation (RTX): Free Stock Analysis Report Palantir Technologies Inc. (PLTR): Free Stock Analysis Report
CTV News
5 hours ago
- CTV News
S&P/TSX composite edges higher in late-morning trading
Pedestrians cross Bay St. in the financial district in Toronto, Friday, Sept. 8, 2023. THE CANADIAN PRESS/Andrew Lahodynskyj TORONTO — Canada's main stock index edged higher in late-morning trading as strength in the industrial sector battled weakness in technology and base metal stocks. The S&P/TSX composite index was up 2.03 points at 27,924.88. In New York, the Dow Jones industrial average was up 74.32 points at 44,986.14. The S&P 500 index was down 22.59 points at 6,426.56, while the Nasdaq composite was down 225.40 points at 21,404.37. The Canadian dollar traded for 72.19 cents US compared with 72.42 cents US on Monday. The October crude oil contract was down 64 cents US at US$62.06 per barrel. The December gold contract was down US$11.90 at US$3,366.10 an ounce. --- This report by The Canadian Press was first published Aug. 19, 2025.
